These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

996 related articles for article (PubMed ID: 17712817)

  • 1. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.
    Russo EB; Guy GW; Robson PJ
    Chem Biodivers; 2007 Aug; 4(8):1729-43. PubMed ID: 17712817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
    Russo E; Guy GW
    Med Hypotheses; 2006; 66(2):234-46. PubMed ID: 16209908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
    Rog DJ; Nurmikko TJ; Friede T; Young CA
    Neurology; 2005 Sep; 65(6):812-9. PubMed ID: 16186518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicinal cannabis extracts for the treatment of multiple sclerosis.
    Smith PF
    Curr Opin Investig Drugs; 2004 Jul; 5(7):727-30. PubMed ID: 15298068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
    Sastre-Garriga J; Vila C; Clissold S; Montalban X
    Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.
    Notcutt W; Price M; Miller R; Newport S; Phillips C; Simmons S; Sansom C
    Anaesthesia; 2004 May; 59(5):440-52. PubMed ID: 15096238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis derivatives and pain. A small role for delta9-tetrahydrocannabinol (THC) in some forms of multiple sclerosis.
    Prescrire Int; 2009 Oct; 18(103):226. PubMed ID: 19882800
    [No Abstract]   [Full Text] [Related]  

  • 10. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.
    Eichler M; Spinedi L; Unfer-Grauwiler S; Bodmer M; Surber C; Luedi M; Drewe J
    Planta Med; 2012 May; 78(7):686-91. PubMed ID: 22411724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis; adverse effects from an oromucosal spray.
    Scully C
    Br Dent J; 2007 Sep; 203(6):E12; discussion 336-7. PubMed ID: 17703180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sativex for the management of multiple sclerosis symptoms.
    Perras C
    Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
    Sagredo O; Pazos MR; Satta V; Ramos JA; Pertwee RG; Fernández-Ruiz J
    J Neurosci Res; 2011 Sep; 89(9):1509-18. PubMed ID: 21674569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.
    Smith PF
    Expert Rev Neurother; 2007 Sep; 7(9):1157-63. PubMed ID: 17868014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.
    Roser P; Juckel G; Rentzsch J; Nadulski T; Gallinat J; Stadelmann AM
    Eur Neuropsychopharmacol; 2008 Aug; 18(8):569-77. PubMed ID: 18544469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Barnes MP
    Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.
    Robson P
    Expert Opin Drug Saf; 2011 Sep; 10(5):675-85. PubMed ID: 21542664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.
    Berman JS; Symonds C; Birch R
    Pain; 2004 Dec; 112(3):299-306. PubMed ID: 15561385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
    Wade D
    Expert Rev Neurother; 2012 Apr; 12(4 Suppl):9-14. PubMed ID: 22509986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.